SBIR Phase II: Serialized Anti-Counterfeit Labeling Technology for Pharmaceutical and Biol — NSF Award to BALLYDEL TECHNOLOGIES IN
The broader impact of this Small Business Innovation Research (SBIR) Phase II project is on the mitigation of the worldwide counterfeit drug market which has a significant impact on public health, brand integrity, and revenue. Specifically, this project aims to develop a state of the art, counterfeit-proof, ID security
| Award title | SBIR Phase II: Serialized Anti-Counterfeit Labeling Technology for Pharmaceutical and Biol |
|---|---|
| Award ID | 2330736 |
| Awardee | BALLYDEL TECHNOLOGIES INC. |
| City | WILMINGTON |
| State | DE |
| Amount obligated | $951,394 |
| Principal investigator | Brendan DeLacy |
| Program | SBIR Phase II |
| Start date | 06/15/2024 |
| Abstract | The broader impact of this Small Business Innovation Research (SBIR) Phase II project is on the mitigation of the worldwide counterfeit drug market which has a significant impact on public health, brand integrity, and revenue. Specifically, this project aims to develop a state of the art, counterfeit-proof, ID security technology that enables vaccine and biologic manufacturers to tag, track, and authenticate its products throughout the supply chain. The technology involves a scalable manufacturi |
| Source | NSF Awards |
$799/mo
Try NSFGrants →